Health and Healthcare
Valeant Offers Even More for Botox-Maker Allergan
Published:
Last Updated:
Just two days ago Valeant raised its offer by $10 a share, from $48.30 to $58.30. The stock portion has remained constant.
Pershing Square Capital Managment, Allergan’s largest shareholder has agreed to elect only stock in Valeant as payment for its 9.7% stake in the Botox maker. Pershing Square’s CEO, Bill Ackman, has agreed to exchange each of the firm’s Allergan shares for 1.22659 shares of Valeant. Ackman said he called Valeant’s CEO this morning and “offered to give up $600 million of value to other Allergan shareholders and exchange our shares for Valeant stock if Valeant were prepared to increase its offer to other Allergan shareholders.”
Allergan has not responded to Valeant’s offer, but the stock is responding by rising nearly 5% to $166.01 in a 52-week range of $81.33 to $170.05.
ALSO READ: Analysts Stocks to Buy for an Aging America
Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.